Home » news »

Misconceptions about opioids affect pain control among cancer patients: a Malaysian survey

 

IMAGE: Abstract 429P – Results of the cross-sectional survey conducted at the Sarawak General Hospital in Malaysia
view more 

Credit: © European Society for Medical Oncology

Singapore, 21 November 2018 – Misconceptions about the use of strong opioids showed to undermine optimal pain control among Asian cancer patients undergoing chemotherapy and radiotherapy according to a cross-sectional survey conducted at the Sarawak General Hospital in Malaysia. (1)

In a study to be presented at the ESMO Asia 2018 Congress, 133 patients with solid tumours across all stages treated with strong opioids were requested to rate their experience of pain during the week before the delivery of the survey questionnaire by using a visual analogue scale (VAS) from 0-10 and to self-assess the impact of pain on daily activities by completing the Brief Pain Inventory-short form (BPI-sf).

Researchers also investigated types of strong opioids used and patient-related barriers to effective cancer pain management; results were assessed by social determinants including ethnic group, religion and education level.

Overall, a good pain control was reported in 62% of survey participants (pain score Greater barriers for pain control were found in patients with higher education levels, which may reflect pervasive misconception of opioids use in social media. Fear of harmful effects from taking opioids was observed to be more common in the Malay community, followed by Chinese and Dayak groups. “These differences may reflect some inequities in access to optimal cancer care in the state, however multiple socio-economic factors may also play a critical role in the use of opioids, thus further investigations are needed”, commented Dr Voon.

Although adequate pain relief is core to supportive care, it is still hindered by the lack of availability or accessibility to opioids in some countries, according to Prof Sumitra Thongprasert from Bangkok Hospital Chiang Mai, Thailand, co-chair of the ESMO Asia 2018 Public Policy programme. “Beliefs and other cultural issues may only partially explain a sub-optimal use of opioids analgesics, and several factors remain to be assessed including how information on benefits of these drugs is delivered by health care providers”, she commented. “More importantly, access to prescription of opioids and government restrictions regarding the total amount that a patient could receive each time can significantly influence access and usage patterns among cancer patients.”

Accessibility issues, costs and regulatory barriers that can limit prescribing and dispensing of opioid analgesics in low- and middle-income countries (LMICs) were firstly mapped in 2013 by the Global Opioid Policy Initiative (GOPI) (2) conducted by ESMO with other international partners and which expanded the results of a similar survey conducted in Europe in 2010. (3) Opioid availability was reported to be low in all 20 surveyed countries in Asia, except for South Korea and Japan, and evidence of over-regulation of opioid prescribing was found in the Asia-Pacific region that may restrict or impair access to pain relief treatments. Outcomes from this initiative also highlighted a concrete need to improve palliative care knowledge among clinicians in Asian countries.

“At present, although the availability of critical medications such as opioids, targeted medicines and immunotherapies may be potentially improved in Asia, accessibility issues will be hard to overcome in the next future due to the high costs of cancer treatments”, continued Thongprasert. “Some countries across Asia/Asia-Pacific are simply not able to provide expensive medicines to local communities. Also, in countries where patients have to pay on their own for cancer treatments, high costs of medicines can be the primary reason of poor quality in cancer care.”

Prof. Nathan Cherny from Shaare Zedek Medical Centre Oncology Institute, Israel, at the time co-coordinator of the Global Opioid Policy Initiative for ESMO, added: “According to the results reported in the paper published in 2013, there is agreement between the WHO, the International Narcotics Control Board, and ESMO, and the 20 international and national palliative care and oncology societies collaborating on the project, (4) about the fact that opioid analgesic therapy is the cornerstone of cancer pain management, and that there is no economic barrier to making opioids available for this indication, and that it must be made a public health priority.”

Strategies to improve accessibility to and availability of cancer medicines in LMICs will be discussed in a thought-provoking debate to be held at the ESMO Asia 2018 Congress in Singapore. (5) “Since reducing cancer medicine costs could take some time, other potential strategies need to be assessed, such as the set-up of different pricing according to economic status; pharmaceutical companies providing Patient Access programme or Technology transfer to LMICs to manufacture their own medicines; availability of quality-assured generic and biosimilar medicines; and Compulsory Licensing of anti-cancer medicines. Beyond regulations, major barriers are likely to remain in these countries due to the rapid pace of development of new medicines, limitation of access to research projects and a lack of new technologies.” added Thongprasert.

Global commitment on ensuring access to anti-cancer medicines has increased over recent years and according to ESMO President Josep Tabernero, cooperation among different stakeholders can contribute to better guiding the Asia-Pacific countries towards improving access to and availability of essential medicines, vaccines, diagnostics and medical devices.

“Overall, there is a need to adequately prioritise limited resources to clinical benefits, and collaborative efforts have resulted in new tools and approaches that can play a critical step in addressing policy issues in LMICs. One such platform is the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) (6,7) which can help governments to review and adjust their respective national medicine lists to ensure that they prioritise the most cost-effective ones that provide the greatest value to patients.”

“Also, by facilitating education and updating of oncology professionals in the Asia-Pacific region, the annual ESMO Asia Congress, launched back in 2014, provides the arena for sharing knowledge as well as discussing and debating major challenges in oncology towards advancing the field and bringing about real and necessary change,” the ESMO President concluded.

###

Notes to Editors

Please make sure to use the official name of the meeting in your reports: ESMO Asia 2018 Congress

Official Congress Hashtag: #ESMOAsia18

References

  1. Abstract 439P – ‘Pain control among cancer patients receiving strong opioids and their perspective towards opioids in a developing coiuntry with a diverse multicultural background’ will be presented by Daniel Lee during the Poster Display Session on Saturday, 24 November, from 18:00 to 19:00 (SGT) in the Exhibition Area. Annals of Oncology, Volume 29, 2018 Supplement 9, doi:10.1093/annonc/mdy426
  2. Global Opioid Policy Initiative: http://www.esmo.org/Policy/Global-Opioid-Policy-Initiative
  3. N.I. Cherny, J.Cleary, W. Scholten, L. Radbruch, J. Torode. ‘The Global Opioid Policy Initiative (GOPI) project to evaluate the availability and accessibility of opioids for the management of cancer pain in Africa, Asia, Latin America and the Caribbean, and the Middle East’, Annals of Oncology, Volume 24, Supplement 11, 1 December 2013
  4. Global Opioid Policy Initiative partners: http://www.esmo.org/Policy/Global-Opioid-Policy-Initiative/Partners
  5. “The reality of accessing cancer care in Asia and Asia/Pacific” to be held on Saturday, 24 November, from 14:30 to 16:00 (SGT) in Room 310
  6. Cherny N, Dafni U, Bogaerts J et al. ESMO-Magnitude of Clinical Benefit Scale Version 1.1 Ann Oncol 2017; 28: 2340-2366.
  7. Cherny NI, Sullivan R, Dafni U et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncol Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573.

Disclaimer

This press release contains information provided by the author of the highlighted abstract and reflects the content of this abstract. It does not necessarily reflect the views or opinions of ESMO who cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct.

About the European Society for Medical Oncology (ESMO)

ESMO is the leading professional organisation for medical oncology. With more than 20,000 members representing oncology professionals from over 150 countries worldwide, ESMO is the society of reference for oncology education and information. ESMO is committed to offer the best care to people with cancer, through fostering integrated cancer care, supporting oncologists in their professional development, and advocating for sustainable cancer care worldwide.Visit http://www.esmo.org

439P – Pain control among cancer patients receiving strong opioids and their perspective towards opioids in a developing country with a diverse multicultural background

D.Z.F. Lee, D.K.L. KIU, V. Pei Jye

Radiotherapy Oncology, Sarawak General Hospital, Kuching, Malaysia,

Background: Strong opioids are commonly used to manage severe pain among cancer patients, however patients’ misconceptions towards strong opioids result in pain under-treatment, reducing their quality of life.

Methods: Patients were invited to fill in a survey inquiring their age, gender, ethic group, religion, education level, occupation, marital status. Pain was measured objectively with a visual analogue scale from 0-10 and effects of pain measured using the Brief Pain Inventory-short form. Patient-related barriers were measured using Barriers Questionnaire-II. Scores were expressed as means with standard deviations and associations were analysed using parametric or non-parametric tests, interpreted at 5% significance.

Results: Of 133 participants, 62% of patients have good pain control however 71% still have moderate to severe interference with daily activities due to pain. Pain intensity correlated positively to daily interferece (p=0.000) of daily activites and belief of fatalism (p=0.001). Patients with higher education levels tend to have strong barriers towards opioids (p=0.000). There were significant difference between ethnic groups on perspective of harmful effects of opioids, with Malay recording greater barriers followed by the Chinese and Dayak communities.

Conclusions: Pain is a multidimensional experience requiring exploration from multiple aspects. Healthcare professionals should educate patients to clear misconceptions regarding opioids and thorough pain assessment is essential.

Clinical trial identification: NMRR-17-2209-37841 (IIR)

Legal entity responsible for the study: National Medical Research Registry of Malaysia

Funding: Has not received any funding

Disclosure: All authors have declared no conflicts of interest.

 

Related Posts

  • No Related Posts